Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ACADEMIA
ACADEMIA
- AGs “Will Energize the Generic Drug Market”: Prof. Sakamaki
June 17, 2015
- MHLW Official Urges Generic Drug Makers to Expand into Overseas Markets
June 17, 2015
- MHLW Official Restates Difficulty of Moving Up Timeline to Attain 80% Generic Share
June 16, 2015
- Tiotropium Positioned in Step 3 and Step 4 Care for Asthma: Japanese Society of Allergology’s Revised Guidelines
June 5, 2015
- Pfizer Poised to Emerge as Global Leader in Oncology: Chief Medical Officer
June 3, 2015
- Xtandi Monotherapy Meets Primary Endpoint in PII Study for Triple-Negative Breast Cancer: Astellas
June 3, 2015
- 3 of 20 Japanese Gastric Cancer Patients Show PR to PD-L1 Inhibitor Avelumab: ASCO
June 3, 2015
- Ibrance Prolongs PFS in Second-Line for Advanced Breast Cancer: ASCO
June 3, 2015
- BBI608, BBI503 Exert Antitumor Activity in Multiple Studies: Sumitomo Dainippon
June 3, 2015
- Pfizer, Merck KGaA Set to Leverage Complementary Tie-Up to Develop PD-L1 Inhibitor
June 2, 2015
- Opdivo Shows OS Rate of 62% in HCC at 12 Months: ASCO
June 1, 2015
- MHLW-Funded Study Calls for Use-Based Development Plans for Combination Drugs
May 7, 2015
- Six Deaths Confirmed through Tofacitinib PMS, Guidelines Not Followed in All Cases
April 30, 2015
- Biometric Society of Japan to Establish Certification System for Biostatisticians
April 17, 2015
- Study Group Recommends “Reference Groups,” Dose-Escalation Studies to Promote Development of Ultra-Orphan Drugs
April 8, 2015
- Medical University Association to Strengthen Collaboration with Industry
April 3, 2015
- Stop Use of SGLT-2 Inhibitors, NSAIDs in Elderly: Japan Geriatrics Society
April 3, 2015
- CRPC Drugs Xtandi, Zytiga Neck-and-Neck in Key Opinion Leader Poll
April 1, 2015
- New Stroke Guidelines to “Strongly Recommend” NOACs for NVAF
March 31, 2015
- Keytruda Demonstrates Superior OS, PFS to Yervoy in Advanced Melanoma in PIII Study: Merck
March 30, 2015
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…